These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 1329642)

  • 41. Evaluations of the Etest for antimicrobial susceptibility testing of Legionella pneumophila, including validation of the imipenem and sparfloxacin strips.
    Rhomberg PR; Jones RN
    Diagn Microbiol Infect Dis; 1994 Nov; 20(3):159-62. PubMed ID: 7874883
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections.
    Hoogkamp-Korstanje JA
    J Antimicrob Chemother; 1997 Sep; 40(3):427-31. PubMed ID: 9338498
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Activity of new quinolones against ciprofloxacin-resistant staphylococci.
    Forstall GJ; Knapp CC; Washington JA
    Antimicrob Agents Chemother; 1991 Aug; 35(8):1679-81. PubMed ID: 1656873
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone.
    Gooding BB; Jones RN
    Antimicrob Agents Chemother; 1993 Feb; 37(2):349-53. PubMed ID: 8043036
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In vitro activity of CP-99,219, a novel 7-(3-azabicyclo[3.1.0]hexyl) naphthyridone antimicrobial.
    Gootz TD; Brighty KE; Anderson MR; Schmieder BJ; Haskell SL; Sutcliffe JA; Castaldi MJ; McGuirk PR
    Diagn Microbiol Infect Dis; 1994 Aug; 19(4):235-43. PubMed ID: 7851087
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In vitro and in vivo antimicrobial activities of T-3811ME, a novel des-F(6)-quinolone.
    Takahata M; Mitsuyama J; Yamashiro Y; Yonezawa M; Araki H; Todo Y; Minami S; Watanabe Y; Narita H
    Antimicrob Agents Chemother; 1999 May; 43(5):1077-84. PubMed ID: 10223917
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In vitro activity of tosufloxacin (A-61827; T-3262) against selected genital pathogens.
    Segreti J; Hirsch DJ; Harris AA; Kapell KS; Orbach H; Kessler HA
    Antimicrob Agents Chemother; 1990 Jun; 34(6):971-3. PubMed ID: 2118330
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vitro activity of temafloxacin against gram-negative bacteria: an overview.
    Hardy DJ
    Am J Med; 1991 Dec; 91(6A):19S-23S. PubMed ID: 1662890
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A comparative study on the efficacy of the new quinolone alatrofloxacin in the treatment of experimental legionellosis in guinea pigs.
    García-de-Lomas J; Millás E; Lázaro MA; Bermejo M; Gimeno C; Navarro D; Sánchez S
    Eur J Clin Microbiol Infect Dis; 1998 Jun; 17(6):420-3. PubMed ID: 9758285
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In-vitro activity of six intracellular antibiotics against Legionella pneumophila strains of human and environmental origin.
    Reda C; Quaresima T; Pastoris MC
    J Antimicrob Chemother; 1994 Apr; 33(4):757-64. PubMed ID: 8056694
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Review of azithromycin activity against Legionella spp.
    Edelstein PH
    Pathol Biol (Paris); 1995 Jun; 43(6):569-72. PubMed ID: 8539085
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Lack of resistance to erythromycin, rifampicin and ciprofloxacin in 98 clinical isolates of Legionella pneumophila.
    Onody C; Matsiota-Bernard P; Nauciel C
    J Antimicrob Chemother; 1997 Jun; 39(6):815-6. PubMed ID: 9222053
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In-vitro activities of temafloxacin, tosufloxacin (A-61827) and five other fluoroquinolone agents.
    Barry AL; Jones RN
    J Antimicrob Chemother; 1989 Apr; 23(4):527-35. PubMed ID: 2745259
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antimicrobial chemotherapy for legionnaires' disease: a review.
    Edelstein PH
    Clin Infect Dis; 1995 Dec; 21 Suppl 3():S265-76. PubMed ID: 8749675
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In vitro activity of CP-74,667. A new fluoroquinolone compared with other quinolones.
    Gu JW; Fang W; Chin NX; Neu HC
    Diagn Microbiol Infect Dis; 1992; 15(7):613-20. PubMed ID: 1330421
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Wild-type MIC distribution and epidemiological cut-off values in clinical Legionella pneumophila serogroup 1 isolates.
    Bruin JP; Ijzerman EP; den Boer JW; Mouton JW; Diederen BM
    Diagn Microbiol Infect Dis; 2012 Jan; 72(1):103-8. PubMed ID: 22100012
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In vitro evaluation of sparfloxacin activity and spectrum against 24,940 pathogens isolated in the United States and Canada, the final analysis.
    Jones RN; Ballow CH; Schentag JJ; Johnson DM; Deinhart JA
    Diagn Microbiol Infect Dis; 1998 May; 31(1):313-25. PubMed ID: 9597392
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Susceptibilities of 123 Xanthomonas maltophilia strains to clinafloxacin, PD 131628, PD 138312, PD 140248, ciprofloxacin, and ofloxacin.
    Pankuch GA; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1994 Feb; 38(2):369-70. PubMed ID: 8192468
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy of NY-198 against experimental Legionnaires disease.
    Kohno S; Yamaguchi K; Dohtsu Y; Koga H; Hayashi T; Hirota M; Saito A; Hara K
    Antimicrob Agents Chemother; 1988 Sep; 32(9):1427-9. PubMed ID: 3196003
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Correlation of MIC value and disk inhibition zone diameters in clinical Legionella pneumophila serogroup 1 isolates.
    Bruin JP; Diederen BM; Ijzerman EP; Den Boer JW; Mouton JW
    Diagn Microbiol Infect Dis; 2013 Jul; 76(3):339-42. PubMed ID: 23583350
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.